News
CRDF
1.080
+1.89%
0.020
Weekly Report: what happened at CRDF last week (0928-1002)?
Weekly Report · 4d ago
Weekly Report: what happened at CRDF last week (0921-0925)?
Weekly Report · 09/28 10:15
Weekly Report: what happened at CRDF last week (0914-0918)?
Weekly Report · 09/21 10:15
Analysts Conflicted on These Healthcare Names: High Tide (HITI), Cardiff Oncology (CRDF) and Benitec Biopharma (BNTC)
TipRanks · 09/15 13:40
Cardiff Oncology Price Target Announced at $9.00/Share by HC Wainwright & Co.
Dow Jones · 09/15 10:38
Cardiff Oncology Raised to Buy From Neutral by HC Wainwright & Co.
Dow Jones · 09/15 10:38
HC Wainwright & Co. Upgrades Cardiff Oncology to Buy, Announces $9 Price Target
Benzinga · 09/15 10:28
Cardiff Oncology upgraded to Buy from Neutral at H.C. Wainwright
TipRanks · 09/15 10:10
Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS) and Cardiff Oncology (CRDF)
TipRanks · 09/14 15:30
Cardiff Oncology Amends Onvansertib License, Resolves Litigation
TipRanks · 09/14 13:47
Cardiff Oncology, Nerviano Medical Sciences reach settlement
TipRanks · 09/14 13:00
Weekly Report: what happened at CRDF last week (0907-0911)?
Weekly Report · 09/14 10:20
Weekly Report: what happened at CRDF last week (0831-0904)?
Weekly Report · 09/07 10:13
Weekly Report: what happened at CRDF last week (0824-0828)?
Weekly Report · 08/31 10:21
Weekly Report: what happened at CRDF last week (0817-0821)?
Weekly Report · 08/24 10:21
Cardiff Oncology downgraded to Market Perform from Outperform at William Blair
TipRanks · 08/17 11:06
Weekly Report: what happened at CRDF last week (0810-0814)?
Weekly Report · 08/17 10:22
Take-Two, Quantum, On, Cardiff, Autodesk Trending With Analysts
TipRanks · 08/15 09:01
Cardiff Oncology Cut to Market Perform From Outperform by William Blair
Dow Jones · 08/12 19:13
William Blair Downgrades Cardiff Oncology to Market Perform
Benzinga · 08/12 19:03
More
Webull provides a variety of real-time CRDF stock news. You can receive the latest news about Cardiff Oncology Inc through multiple platforms. This information may help you make smarter investment decisions.
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company advancing cancer treatments focused on Polo-like Kinase 1 (PLK1) inhibition, a validated oncology target with practice-changing potential. The Company's lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor being evaluated in a Phase II trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML). The Company's clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.